Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Recordati Acquires Six OTC Products

European pharmaceutical group Recordati Tuesday announced the acquisition of the marketing authorizations, the trademarks and additional assets concerning six OTC pharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH & Co. oHG.

The products acquired are JHP-Rödler, BetadormD, Rhinopront, Collomack Topical, Tirgon and Xitix. The 2012 sales for the six products are estimated at around EUR 6 million.

Giovanni Recordati, chairman and CEO of the Recordati Group, said, "The OTC pharmaceutical segment in Germany represents 52 percent share in units of the overall pharmaceutical market."

Recordati added that together with the existing OTC portfolio, the German subsidiary will now be able to better exploit the OTC market potential by building a dedicated sales organization.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Yukiya Amano, Director General of the International Atomic Energy Agency (IAEA), said Monday that nuclear programs of the Democratic People's Republic of Korea (DPRK) and Iran remain matters of serious concern. The head of the United Nations nuclear watchdog made the remarks at the opening of the... Stocks largely turned in a lackluster performance during trading on Monday, as traders looked ahead to the Federal Reserve's monetary policy announcement later this week. Technology stocks saw significant weakness, however, resulting in a sharp drop by the tech-heavy Nasdaq. While most Americans support President Barack Obama's decision to take action against the terrorist group ISIS, the results of a new NBC News/Wall Street Journal/Annenberg poll found that the vast majority lack confidence that the U.S. will achieve its goals.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.